Search Results 1831-1840 of 17837 for Substance+dependence
Immunotoxins, such as inotuzumab ozogamicin, are antibodies linked to a toxic substance and may help find cancer cells that express CD22 and kill them without ...
UP-NEXT is a double-blind, randomized, placebo controlled study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an ...
See Mayo's clinical trials website and search for a study by condition, treatment or drug name. Mayo Clinic researchers continually develop new studies, so ...
... drug. Be able to understand the study procedures, agree to participate in the study program, and voluntarily provide written Informed Consent. Exclusion ...
during the period of therapy and for 90 days after the last dose of study drug. Provide written informed consent. Willingness to provide mandatory blood ...
By condition, treatment or drug name. Search tips. Influenza and Other Emerging Diseases Registry. Print details. Share; Facebook · Twitter. Overview ...
... abuse potential. Pagination Clinical studies. PrevPrevious Page · Go to page 44 · Go to page 55 · Go to page 66 · Go to page 77 · NextNext Page · Medical ...
... drug and must continue this therapy throughout the treatment phase * Palliative radiotherapy (for example \[eg\], soft tissue lesions) must be completed ...
Drug- or toxin-induced. Have diabetes mellitus (DM) and meets any of the following criteria: Diagnosis of DM pre-dates the diagnosis of CIDP;; Has ever ...
By condition, treatment or drug name. Search tips. A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.